Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Biogen Inc.    BIIB

BIOGEN INC.

(BIIB)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
01/15/2021 01/19/2021 01/20/2021 01/21/2021 01/22/2021 Date
275.84(c) 273.84(c) 270.28(c) 270.12(c) 269.44(c) Last
1 765 034 1 214 024 1 293 364 806 526 685 483 Volume
-1.59% -0.73% -1.30% -0.06% -0.25% Change
More quotes
Financials (USD)
Sales 2020 13 392 M - -
Net income 2020 4 276 M - -
Net Debt 2020 2 814 M - -
P/E ratio 2020 10,1x
Yield 2020 -
Sales 2021 11 283 M - -
Net income 2021 3 230 M - -
Net Debt 2021 99,5 M - -
P/E ratio 2021 12,1x
Yield 2021 -
Capitalization 41 462 M 41 462 M -
EV / Sales 2020 3,31x
EV / Sales 2021 3,68x
Nbr of Employees 7 400
Free-Float 86,1%
More Financials
Company
Biogen Inc. is one of the world's leaders in the design, manufacturing, and marketing of therapeutic products. Net sales break down by source of income as follows: - sales of medicines (79.2%): for treating multiple sclerosis, chronic psoriasis in adults, rheumatoid arthritis, cancers, etc.; - royalties (15.9%); - other (4.9%): primarily revenues from partnership agreements. 
More about the company
Notations Surperformance© of Biogen Inc.
Trading Rating : Investor Rating :
More Ratings
All news about BIOGEN INC.
01/22PRESS RELEASE : BB BIOTECH AG: Vaccines leading -2-
DJ
01/19BIOGEN : Morgan Stanley Adjusts Biogen PT to $352 From $357, Maintains Overweigh..
MT
01/14BIOGEN : Aducanumab data review and Q&A with Alzheimer's Disease International
PU
01/13BIOGEN : to Report Fourth Quarter and Full Year 2020 Financial Results February ..
PU
01/13DENALI THERAPEUTICS : Strategic Outlook, Upcoming Data for DNL310 Warrant Price ..
MT
01/13BIOGEN : A statement about Biogen Political Action Committee
PU
01/12DEADLINE TODAY : The Schall Law Firm Announces the Filing of a Class Action Laws..
PR
01/11EISAI : Lilly Alzheimer's drug slows mental, functional decline in mid-stage tri..
RE
01/11ELI LILLY AND : Lilly Alzheimer's Drug Helped Patients in Small Trial -- Update
DJ
01/11BIOGEN : Announces First Patient Treated in RESPOND Study Evaluating Benefit of ..
AQ
01/11BIOGEN : to Participate in Webinar with Alzheimer's disease International on Jan..
AQ
01/11BIOGEN : to Launch Study to Develop Digital Biomarkers of Cognitive Health Using..
MT
01/11BIOGEN : to Launch Pioneering Study to Develop Digital Biomarkers of Cognitive H..
AQ
01/11ELI LILLY AND : Lilly Alzheimer's Drug Helped Patients in Small Trial
DJ
01/11EISAI : Lilly says Alzheimer's drug slows clinical decline in mid-stage trial
RE
More news
News in other languages on BIOGEN INC.
01/22BB Biotech a étoffé ses gains en 2020 et va en faire profiter ses actionnaire..
01/22BB Biotech 2020 mit etwas höherem Gewinn und erneuter Dividendenerhöhung
01/11EISAI : Medicamento de Eli Lilly para el alzhéimer retrasa declive mental y func..
01/02Die Tops und Flops 2020 im Nasdaq 100
2020BIOGEN : accord de collaboration avec Sage Therapeutics
More news
Analyst Recommendations on BIOGEN INC.
More recommendations
Chart BIOGEN INC.
Duration : Period :
Biogen Inc. Technical Analysis Chart | BIIB | US09062X1037 | MarketScreener
Technical analysis trends BIOGEN INC.
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 33
Average target price 294,04 $
Last Close Price 269,44 $
Spread / Highest target 67,0%
Spread / Average Target 9,13%
Spread / Lowest Target -35,1%
EPS Revisions
Managers and Directors
NameTitle
Michel Vounatsos Chief Executive Officer & Director
Stelios B. Papadopoulos Chairman
Michael R. McDonnell Chief Financial Officer & Executive Vice President
Alfred W. Sandrock Chief Medical Officer & EVP-Research & Development
Mark Hernon Chief Information Officer & Senior Vice President
Sector and Competitors
1st jan.Capitalization (M$)
BIOGEN INC.10.04%41 462
CSL LIMITED-3.03%96 409
SAMSUNG BIOLOGICS CO.,LTD.-3.87%47 496
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO.,LTD.10.88%40 484
ALEXION PHARMACEUTICALS, INC.1.04%34 956
UCB3.67%20 143